The Department of Health and Human Services, Department of Justice, and Federal Trade Commission Dec. 7  several new actions to promote competition in health care and support lower prescription drug costs. Among other things, the agencies will seek public input on the impact of private equity and corporate control in health care to identify areas for future regulation and enforcement; improve information sharing to better identify anticompetitive 鈥渞ollups鈥 that evade antitrust scrutiny; and appoint an HHS chief competition officer and health care chief counsels at DOJ and FTC. 

In addition, the Centers for Medicare & Medicaid Services today released  for Federally Qualified Health Centers and Rural Health Clinics and plans to seek public input early next year to strengthen data and transparency in the Medicare Advantage market, the Administration said. The Department of Commerce and HHS also proposed a framework to promote access to taxpayer-funded inventions, including medical treatments.

Related News Articles

Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the鈥
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug鈥
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy鈥
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation鈥
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at鈥
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥